Ask AI
ProCE Banner Activity

CME

Research Focus in Advanced NSCLC: Emerging Insights on Next-Generation KRAS G12C Inhibitors

Text Module

An expert review of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), with a focus on ongoing research and strategies to overcome barriers limiting current standards of care, including emerging combination approaches and next-generation KRAS G12C inhibitors.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: April 30, 2026

Expiration: October 29, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group and Lilly.

Genentech, a member of the Roche Group

Lilly

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with non-small-cell lung cancer.

Program Learning Goal

This activity aims to improve learners’ knowledge, confidence, and competence in integrating novel targeted agents to improve outcomes in patients with KRAS G12C–mutated non-small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with NSCLC who may be eligible for treatment with next-generation KRAS G12C–targeted therapies when they become available

  • Consider how next-generation KRAS G12C–targeted agents in late-phase clinical trials might be integrated into real-world clinical practice for patients with NSCLC

  • Discuss with colleagues and patients ongoing advances in targeting KRAS G12C for solid tumors

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Christine Bestvina, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Genentech, Jazz, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer, Summit, Turning Point Therapeutics, Voronoi; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb.

Luis Paz-Ares, MD, PhD: honoraria: Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Jazz, Lilly, Merck Serono, Mirati, Novartis, Pfizer, PharmaMar, Roche/Genentech, Sanofi, Takeda; founder and board member: ALTUM Sequencing, Stab Therapeutics; research funding (to Institution): AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, PharmaMar; speaker: Bristol Myers Squibb, Lilly, Merck Serono, Merck Sharp & Dohme, Pfizer, Roche/Genentech.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2026, through October 29, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.